Related Experiment Video

Updated: Jun 5, 2025

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

15.0K

Resurgence of Pediatric Mycoplasma pneumoniae Infections in Southeast Texas, November 2023-June 2024

Margaret Taylor Danner1, Heather Colvin Binns2, Khanh Nguyen1

  • 1Department of Pediatrics, Division of Infectious Diseases, Baylor College of Medicine, Houston, Texas, USA.

Journal of the Pediatric Infectious Diseases Society
|December 14, 2024
PubMed

Insights

Mycoplasma pneumoniae infections in children surged from November 2023 to June 2024. Confirmed cases during this period frequently involved severe respiratory illness or extrapulmonary symptoms.

Area of Science:

  • Pediatrics
  • Infectious Diseases
  • Microbiology

Background:

  • Mycoplasma pneumoniae is a common cause of respiratory infections in children.
  • Understanding trends in M. pneumoniae infections is crucial for public health.
  • Recent epidemiological data on M. pneumoniae resurgence is limited.

Purpose of the Study:

  • To analyze the incidence and clinical characteristics of Mycoplasma pneumoniae infections in children.
  • To identify trends in M. pneumoniae polymerase chain reaction (PCR) positivity.
  • To describe the clinical manifestations associated with M. pneumoniae resurgence.

Main Methods:

  • Retrospective review of pediatric cases tested for M. pneumoniae.
  • Data collected from January 1, 2020, to June 30, 2024.
  • Analysis of M. pneumoniae PCR positivity rates and clinical outcomes.

Main Results:

  • M. pneumoniae PCR positivity increased significantly from November 2023, reaching a peak of 18.3% in June 2024.
  • The resurgence period was characterized by a higher proportion of children with laboratory-confirmed M. pneumoniae infections.
  • Children with confirmed infections often presented with severe respiratory disease or extrapulmonary manifestations.

Conclusions:

  • A notable resurgence of Mycoplasma pneumoniae infections occurred in children between late 2023 and mid-2024.
  • This resurgence was associated with severe clinical presentations, including respiratory and extrapulmonary disease.
  • Continued surveillance and awareness of M. pneumoniae are essential for managing pediatric respiratory infections.
Keywords:
Mycoplasma pneumoniaatypical pneumoniaepidemiologyreactive infectious mucocutaneous eruptionwalking pneumonia

More Related Videos

Antigen-Capture Enzyme-Linked Immunosorbent Assay for Specific Detection of Mycoplasma pneumoniae06:04

Antigen-Capture Enzyme-Linked Immunosorbent Assay for Specific Detection of Mycoplasma pneumoniae

Published on: February 24, 2023

2.3K
Author Spotlight: Advancements in Multiplex Detection of Respiratory Viruses03:53

Author Spotlight: Advancements in Multiplex Detection of Respiratory Viruses

Published on: November 10, 2023

1.1K

Related Concept Videos

Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
208
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
156
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
211
Vaccinations01:51

Vaccinations

Overview
44.1K
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
298
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
220